Could you describe your career background?
I began my career in the city in 2011, starting out in corporate broking and equity sales. I worked for a variety of firms including Daniel Stewart and Northland Capital Partners. It was during this time that I first came across ValiRx – as an AIM-listed company - and took the opportunity to move into the biotechnology sector. Since then, I have fully immersed myself in the industry, and continue to learn new things every day from the talented scientists I work with.
What does your role at ValiRx involve?
At ValiRx, I am responsible for enhancing the reputation of the company and working closely with city firms to identify new therapeutic assets that may be beneficial to incorporate into the ValiRx portfolio.
My role also includes liaising with new and existing shareholders and building trusting relationships with strategic partners. A recent example of the way we cultivate strong relationships with academic institutions is our Cytolytix project, in which we signed an IP license agreement with King’s College London to progress the preclinical development of its triple negative breast cancer treatment, CLX001.
We are looking forward to forming similar partnerships with more academic institutions to help accelerate the development of innovative ideas. This will be further supported by the launch of our new laboratory facilities this year.
How has your brokering experience assisted you in your role at ValiRx?
I feel that my previous career experience has allowed me to bring a fresh, commercial, and proactive approach to ValiRx. Over the years, I have been heavily involved in refreshing ValiRx’s position as a business, and translating this business proposition to ensure that it is attractive to both the market and institutional investors.
What do you most enjoy about working at ValiRx?
As a company, ValiRx fosters a culture of positivity and transparency, as well as offering a supportive working environment. This helps us to collaborate, share knowledge and expertise, and support each other in achieving optimal outcomes.
The team is small – but growing – which has enabled me to gain insight and exposure to all aspects of the business. Our CEO, Dr Suzy Dilly, is friendly and approachable, and leads the business with honesty and integrity. She is using her extensive range of knowledge and expertise to steer the company towards a bright, exciting future.
I am personally looking forward to welcoming future new recruits as we continue to grow and expand our offering.
To learn more about ValiRx’s board of directors and management team, click here.